Integrated BioPharma, Inc.
INBPOTCConsumer Defensive● Active
$0.18
+$0.00(+1.48%)
Market Cap$5696643
P/E Ratio—
52W High$0.42
52W Low$0.17
Integrated BioPharma, Inc. (INBP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INBP · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $54.35M | $50.32M | $50.67M | $56.25M | $63.56M |
| Cost of Revenue | $48.79M | $46.43M | $46.61M | $49.69M | $54.08M |
| Gross Profit | $5.56M | $3.88M | $4.06M | $6.55M | $9.48M |
| Gross Margin %(computed) | 10.23% | 7.72% | 8.01% | 11.65% | 14.92% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $3.54M | $3.63M | $3.94M | $3.81M | $3.70M |
| Operating Income | $2.02M | $0.25M | $0.12M | $1.97M | $5.78M |
| Operating Margin %(computed) | 3.72% | 0.50% | 0.24% | 3.50% | 9.10% |
| Interest Income | $0.09M | $0.07M | $0.01M | $0.00M | $0.00M |
| Interest Expense | $0.05M | $0.05M | $0.04M | $0.13M | $0.26M |
| Income Before Tax | $2.06M | $0.27M | $0.10M | $2.60M | $7.25M |
| Income Tax Expense | $1.25M | $0.16M | $0.13M | ($1.24M) | ($0.77M) |
| Net Income | $0.81M | $0.11M | ($0.03M) | $3.84M | $8.01M |
| Net Margin %(computed) | 1.49% | 0.22% | -0.07% | 6.82% | 12.61% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.03 | $0.00 | $-0.00 | $0.13 | $0.27 |
| Wtd Avg Shares | 30.30M | 30.07M | 29.95M | 29.84M | 29.70M |
| EBITDA | $3.38M | $1.47M | $1.27M | $3.56M | $6.61M |
| EBITDA Margin %(computed) | 6.21% | 2.93% | 2.51% | 6.33% | 10.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Integrated BioPharma, Inc. data
About Integrated BioPharma, Inc. (INBP) Income Statement
Integrated BioPharma, Inc. (INBP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INBP reported revenue of $0.05B, gross profit of $0.01B (gross margin 10.23%), and net income of $0.00B — a net profit margin of 1.49%.
Frequently asked questions
INBP · 4 questionsIntegrated BioPharma, Inc. (INBP) reported revenue of $0.05B for 2025, up 8.0% year-over-year.
INBP revenueINBP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08